Clinical trials have demonstrated that ceritinib can be highly effective in shrinking tumors and prolonging progression-free survival in patients with ALK-positive NSCLC. The efficacy of ceritinib has been observed even in patients who have developed resistance to other ALK inhibitors, making it a valuable option in the treatment landscape of ALK-positive lung cancer.
